期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血液透析患者肌少症的危险因素及其干预措施的研究进展 被引量：5

Research progress in the risk factors and intervention measures for sarcopenia in hemodialysis patients
下载PDF
导出
摘要 本文对血液透析患者肌少症的发生情况、危险因素及其干预措施进行综述,旨在提高医务人员对血液透析合并肌少症的关注度,为临床医务人员开展干预工作提供依据。 This paper reviews the risk factors and intervention measures for sarcopenia in hemodialysis patients,in order to raise the alertness in medical staff on sarcopenia in hemodialysis patients,and to provide references for clinicians to carry out intervention measures for the sarcopenia.
作者 才智 芦桂芝 马艳玲 丑新宇 CAI Zhi;LU Gui-zhi;MA Yan-ling;CHOU Xin-yu(School of Nursing,Harbin Medical University,Harbin 150086,China;Infection Control Department,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)
机构地区 哈尔滨医科大学护理学院 哈尔滨医科大学附属第二医院感染监控科
出处 《中国血液净化》 CSCD 2020年第5期323-326,共4页 Chinese Journal of Blood Purification
关键词 血液透析 肌少症 危险因素 干预措施 综述 Hemodialysis Sarcopenia Risk factors Intervention measures Review
分类号 R45 [医药卫生—治疗学]
  • 相关文献

参考文献5

二级参考文献76

  • 1Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J].J Am Soc Nephrol, 2004, 15:2208-2218.
  • 2Itoh N, Ornitz DM. Evolution of the FGF and FGFR gene families[J]. Trends Genet, 2004, 20:563-569.
  • 3Yan X, Yokote H, Jing Let al. Fibroblast growth factor 23 reduces expression of type-IIa Na+/Pi co-transporter by signaling through a receptor function ally distinct from the known FGFRs in opossum kidney cells[J]. Genes Cells, 2005,10:489-502.
  • 4Kazama JJ, Gejyo F, Shigematsu T, et al. Role of circulating fihroblast growth factor 23 in the development of secondary hyperparathyroidism[J]. Ther Apher Dial, 2005, 9:328-330.
  • 5Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease[J].J Am Soc Nephrol, 2004,16: 520-528.
  • 6Forley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of calcium and phosphate metabolism in chronic renal disease [J].Am J Kidney Dis, 1998,32: S112-S119.
  • 7Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis[J].AmJ Kidney Dis, 2003,42 (Suppl 1): 24-29.
  • 8Hutchison, Alastair J. Improving phosphate-binder therapy, a way forward[J]. Nephrol dial Transplant, 2004,19(Suppl 1): 19-24.
  • 9Bellasi A, Kooienga L, Block GA. Phosphate binders: New products and challenges[J]. Bemodial Intern, 2006, 32: S112- S119.
  • 10Fouque D, Pelletier S, Mafra D, et al. A proposed nomenclature and diagnostic criteria for protein - energy wasting in acute and chronic kidney disease. Kidney Int,2008,73 (4) :391 - 398.

共引文献95

同被引文献54

引证文献5

二级引证文献8

中国血液净化
2020年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部